NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
Clinical Trials
68 trialsNCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT00534469 2025-12-02
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Phase 2 Completed
NCT04107727 2025-09-02
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
PETHEMA Foundation
Phase 2 Completed
NCT02185768 2025-07-04
IDASPHERE II
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02937662 2025-05-30
Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT01822015 2025-04-29
Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT01518556 2025-03-20
IDAML
Konkuk University Medical Center
Phase 1/2 Completed
NCT02688140 2025-02-26
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT02135874 2024-03-22
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02013648 2024-02-23
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)
University of Ulm
Phase 3 Completed
NCT02441803 2024-02-22
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04687098 2023-06-27
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase 2 Completed
NCT00198978 2023-03-20
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Goethe University
Phase 4 Completed
NCT00199056 2023-03-20
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
Goethe University
Phase 4 Completed
NCT00199095 2023-03-20
Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
Goethe University
Phase 4 Completed
NCT03194932 2023-02-14
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00876031 2022-11-08
CWS-2007-HR
University Hospital Tuebingen
Phase 3 Completed
NCT01154439 2022-10-26
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 1 Completed
NCT00482833 2022-10-12
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT00198991 2022-08-18
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Goethe University
Phase 4 Completed
NCT02464657 2021-10-07
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02249091 2021-08-25
A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
GSO Global Clinical Research BV
Phase 2 Completed
NCT02144675 2021-08-24
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT01180322 2020-12-31
azacitidine
University of Ulm
Phase 2 Completed
NCT00831766 2020-12-22
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00067028 2020-12-08
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02046122 2020-12-03
Adoptive Transfer of Haplo-identical DLI for AML and MDS
Duke University
Phase 1/2 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT03661515 2020-05-20
FLAGINEXOR
PETHEMA Foundation
Phase 1 Completed
NCT02560025 2020-05-05
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Massachusetts General Hospital
Phase 2 Completed
NCT01540812 2020-03-09
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
PETHEMA Foundation
Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02652871 2019-11-15
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01794702 2019-05-30
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00002565 2018-11-14
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01025154 2018-10-09
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00422591 2018-08-23
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00542971 2018-08-23
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01692197 2018-07-03
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03349957 2018-04-25
TANDEM-IDA
University Hospital, Montpellier
Completed
NCT01831232 2017-11-17
Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase NA Completed
NCT00151242 2017-09-20
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
University of Ulm
Phase 2/3 Completed
NCT00151255 2017-04-19
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
University of Ulm
Phase 3 Completed
NCT00193973 2017-02-17
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Trans Tasman Radiation Oncology Group
Phase 2 Completed
NCT00528398 2017-02-06
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
City of Hope Medical Center
Phase 2 Completed
NCT01700413 2016-01-28
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase 2 Completed
NCT00656617 2015-03-09
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00408278 2014-10-28
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
PETHEMA Foundation
Phase 4 Completed